
IGC Stock Forecast & Price Target
IGC Analyst Ratings
Bulls say
IGC Pharma is focused on developing cannabinoid-based therapies for various diseases and has a positive outlook due to its high enrollment rate (over 70%) in its Phase 2 CALMA trial of IGC-AD1 for agitation associated with Alzheimer's dementia, upcoming milestones in mid-2026 for both the CALMA trial completion and the release of its AI beta program, its favorable current valuation and projected significant upside in its NPV analysis, and its strong focus on Alzheimer's disease, which is a large and growing market with no known cure or effective treatments.
Bears say
IGC Pharma is an early-stage drug development company with minimal revenue and a high net loss, reporting positive interim results for its Alzheimer's disease drug candidate IGC-AD1. However, despite a potential market opportunity and a recent increase in its price target, there are still significant risks for investors, such as balance sheet and liquidity concerns, regulatory hurdles, and potential competition.
This aggregate rating is based on analysts' research of India Globalization Capital and is not a guaranteed prediction by Public.com or investment advice.
IGC Analyst Forecast & Price Prediction
Start investing in IGC
Order type
Buy in
Order amount
Est. shares
0 shares